About us

About us

Welcome to Davipharm

the one you trust

Domestic manufacturer with European standards

We are one of the leading domestic manufacturers of high-quality generic drugs. Established in 2004, certified in 2006 with WHO-GMP, in 2014 Davipharm reached first 100 registered products and started exporting its medicinal products to the Philippines and Cambodia. Since 2016 in top 5 local pharmaceutical companies. In 2017 Adamed Pharma S.A. acquired the controlling stake in Davipharm to upgrade the production standards, implement the EU-GMP (expected early 2021), execute technology transfers and develop export. Our goal is to strengthen our position in the domestic market, focus on R&D excellence, new product launches, contract manufacturing and create SE Asia export hub.

Davipharm – the one you trust

In 2020 Davipharm, with its annual sales of around USD 30 million, has continued to grow faster than the market. In local ethical pharmaceuticals MATQ12020 by IQVIA, Davipharm grew 16.56% while the market increased 13.64%*. Highly qualified and experienced team, international know-how, flexibility and speed of action, openness and innovativeness, transfer of processes and technologies enable this impressive growth and build the image of a reliable partner and high-quality affordable local drugs manufacturer.
*Source: IQVIA, MATQ12020

Vietnam’s First HP Zone

On 16 April 2021, Davipharm announced the certification of Vietnam’s first High Potency (HP) Drugs Zone for the production of cytotoxic/cytostatic oral solids. These are oncological drugs in hard shell capsules, tablets, and coated tablets. According to new regulations from Vietnam’s Ministry of Health, as well as guidelines from the World Health Organization (WHO), European Medicines Agency (EMA) and Pharmaceutical Inspection Co-operation Scheme (PIC/S), the production of certain products containing hazardous substances must be run at separate premises meeting specific criteria.

Davipharm’s portfolio includes 28 high potency (HP) drugs, among them oncology drugs for treatment of breast cancer, leukemia, pancreas, colorectal, stomach, cervix, prostate and lung cancer and glioblastoma.

We have the capacity to produce batches from 15kg to 100kg with an annual output of 500 million units of HP drugs. 

The total capacity of the factory is 1,8 billion units a year.